We could not find any results for:
Make sure your spelling is correct or try broadening your search.
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including dire... IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. Show more
IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma PR...
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers PR Newswire SOUTH SAN...
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 11, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 11, 2024 /PRNewswire/...
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire SOUTH SAN FRANCISCO...
IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 IDE892 is...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 6, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 6, 2024 /PRNewswire/...
IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024 SOUTH SAN FRANCISCO, Calif., Dec. 2, 2024...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 29, 2024 SOUTH SAN FRANCISCO, Calif., Nov. 29, 2024 /PRNewswire/...
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 Brings over 20-year global commercialization experience in oncology with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.59 | -2.27887215141 | 25.89 | 27.15 | 24.475 | 1233512 | 25.54127832 | CS |
4 | -1.15 | -4.34782608696 | 26.45 | 28.65 | 24.475 | 952580 | 26.50124139 | CS |
12 | -6.42 | -20.2395964691 | 31.72 | 32.67 | 24.475 | 926578 | 28.12285218 | CS |
26 | -11.955 | -32.0896523957 | 37.255 | 44.42 | 24.475 | 885028 | 32.94447582 | CS |
52 | -9.76 | -27.8379920137 | 35.06 | 47.735 | 24.475 | 865850 | 36.77704508 | CS |
156 | 2.01 | 8.63031343924 | 23.29 | 47.735 | 8.14 | 630771 | 27.74717994 | CS |
260 | 16.55 | 189.142857143 | 8.75 | 47.735 | 2.95 | 460042 | 26.01809455 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions